Literature DB >> 28215412

Relation of Low-Density Lipoprotein Cholesterol to Ischemic Stroke in Patients With Nonvalvular Atrial Fibrillation.

Zhiyong Qi1, Hua Chen1, Zhichao Wen1, Fei Yuan1, Huanchun Ni1, Wen Gao1, Jun Shen1, Jian Li1, Yangyi Lin1, Ying Shan1, Bo Jin1, Pingping Yan1, Haiming Shi1, Xinping Luo2.   

Abstract

Low-density lipoprotein cholesterol (LDL-C) has been demonstrated as an independent risk factor of ischemic stroke, but the association of LDL-C with ischemic stroke in patients with nonvalvular atrial fibrillation (AF) remains uncertain. Our objective was to explore whether LDL-C could refine stroke stratification in patients with AF. A total of 424 nonvalvular patients with AF with ischemic stroke and 391 ones without ischemic stroke were enrolled. No patient had received antithrombotic therapy. Multivariate logistic regression analysis showed that LDL-C was an independent predictor of ischemic stroke in patients with AF, with the adjusted odds ratio of 2.004 (95% confidence interval 1.624 to 2.473; p <0.001). The receiver operating characteristic analysis revealed that the best cut-off value of LDL-C to predict ischemic stroke in patients with AF was 2.48 mmol/L with 56.3% sensitivity and 66.3% specificity (area under the curve: 0.651, p <0.001). In the subgroup analysis based on different CHA2DS2-VASc scores, the predictive value of LDL-C remained significant in patients with a CHA2DS2-VASc score of ≤5. In conclusion, LDL-C was an independent predictor of ischemic stroke, which could potentially refine stroke stratification in patients with AF. A prospective study with a large number of patients is required to validate the current findings.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28215412     DOI: 10.1016/j.amjcard.2016.12.031

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  9 in total

1.  Low-/high-density lipoprotein cholesterol ratio and carotid plaques in patients with coronary heart disease: a Chinese cohort study.

Authors:  Zhu Li; Qi Cheng; Yijia Liu; Xufeng Cheng; Shuo Wang; Yuanyuan He; Xu Wang; Mengnan Huang; Yue Li; Xiaoxue Xue; Yilan Xu; Lin Li; Yanchao Zheng; Rongrong Yang; Shan Gao; Chunquan Yu
Journal:  Lipids Health Dis       Date:  2021-10-27       Impact factor: 3.876

2.  Relationship between serum lipid levels and ischemic stroke in patients with atrial fibrillation: a nested case-control study based on the China Atrial Fibrillation Registry.

Authors:  Fei Li; Xin Du; Liu He; Chao Jiang; Shijun Xia; Changsheng Ma; Jianzeng Dong
Journal:  BMC Cardiovasc Disord       Date:  2021-09-08       Impact factor: 2.298

Review 3.  Role of New Potential Biomarkers in the Risk of Thromboembolism in Atrial Fibrillation.

Authors:  Mario Piergiulio Pezzo; Antonella Tufano; Massimo Franchini
Journal:  J Clin Med       Date:  2022-02-09       Impact factor: 4.241

4.  Left Atrial Appendage Thrombus in Patients with Nonvalvular Atrial Fibrillation before Catheter Ablation and Cardioversion: Risk Factors beyond the CHA2DS2-VASc Score.

Authors:  Yangwei Cai; Qingsong Xiong; Shaojie Chen; Xi Jiang; Jia Liao; Weijie Chen; Lili Zou; Lei Su; Yefeng Zhu; Yuehui Yin; Zhiyu Ling
Journal:  J Cardiovasc Dev Dis       Date:  2022-01-30

5.  Association between lipoprotein(a) and thromboembolism in patients with non-valvular atrial fibrillation: a cross-sectional study.

Authors:  Jie Song; Xiaoxue Zhang; Meng Wei; Yakun Bo; Xianhui Zhou; Baopeng Tang
Journal:  Lipids Health Dis       Date:  2022-08-25       Impact factor: 4.315

Review 6.  A Review of Biomarkers for Ischemic Stroke Evaluation in Patients With Non-valvular Atrial Fibrillation.

Authors:  Luxiang Shang; Ling Zhang; Yankai Guo; Huaxin Sun; Xiaoxue Zhang; Yakun Bo; Xianhui Zhou; Baopeng Tang
Journal:  Front Cardiovasc Med       Date:  2021-07-01

7.  Dyslipidemia and Risk of Cardiovascular Events in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Therapy: Insights From the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) Trial.

Authors:  Tymon Pol; Claes Held; Johan Westerbergh; Johan Lindbäck; John H Alexander; Marco Alings; Cetin Erol; Shinya Goto; Sigrun Halvorsen; Kurt Huber; Michael Hanna; Renato D Lopes; Witold Ruzyllo; Christopher B Granger; Ziad Hijazi
Journal:  J Am Heart Assoc       Date:  2018-02-01       Impact factor: 5.501

8.  LDL-C/HDL-C is associated with ischaemic stroke in patients with non-valvular atrial fibrillation: a case-control study.

Authors:  Xiao-Xue Zhang; Meng Wei; Lu-Xiang Shang; Yan-Mei Lu; Ling Zhang; Yao-Dong Li; Jiang-Hua Zhang; Qiang Xing; Zu Kela Tu-Erhong; Bao-Peng Tang; Xian-Hui Zhou
Journal:  Lipids Health Dis       Date:  2020-10-07       Impact factor: 3.876

Review 9.  Relationship between lipoproteins, thrombosis, and atrial fibrillation.

Authors:  Wern Yew Ding; Majd B Protty; Ian G Davies; Gregory Y H Lip
Journal:  Cardiovasc Res       Date:  2022-02-21       Impact factor: 10.787

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.